Karyopharm Therapeutics I... (KPTI)
NASDAQ: KPTI
· Real-Time Price · USD
6.55
-0.11 (-1.65%)
At close: Sep 26, 2025, 3:59 PM
6.39
-2.44%
After-hours: Sep 26, 2025, 05:49 PM EDT
Karyopharm Therapeutics Revenue Breakdown
| Period Ending | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| License and Service Revenue | 7.62M | 8.2M | 12.86M | 8.75M | 12.07M | 6.41M | 4.45M | 5.56M | 5.61M | 8.74M | 437K | 1.62M | 6.53M |
| License and Service Revenue Growth | -7.02% | -36.24% | +46.86% | -27.50% | +88.46% | +44.02% | -20.06% | -0.84% | -35.78% | +1899.31% | -72.99% | -75.23% | n/a |
| Other Royalty Revenue | 100K | n/a | n/a | n/a | n/a | n/a | n/a | 500K | 400K | 200K | 1M | 1.4M | 1M |
| Other Royalty Revenue Growth | n/a | n/a | n/a | n/a | n/a | n/a | -100.00% | +25.00% | +100.00% | -80.00% | -28.57% | +40.00% | n/a |
| Royalty Revenue | 1M | n/a | n/a | n/a | n/a | n/a | n/a | 1.5M | 400K | n/a | n/a | n/a | n/a |
| Royalty Revenue Growth | n/a | n/a | n/a | n/a | n/a | n/a | n/a | +275.00% | n/a | n/a | n/a | n/a | n/a |
Operating Expense Breakdown
| Period Ending | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 28.48M | 27.35M | 27.19M | 27.63M | 31.07M | 29.55M | 30.69M | 30.8M | 34.48M | 35.91M | 34.65M | 34.65M | 37.34M | 38.77M | 34.56M | 35.1M | 36.53M | 37.65M | 33.93M | 30.97M | 30.84M | 30.68M | 28.39M | 25.27M | 24.66M | 27.1M | 18.77M | 12.97M | 9.49M | 7.62M | 6.15M | 5.82M | 6.63M | 6.26M | 6.54M | 5.9M | 5.96M | 5.55M | 5.26M | 4.76M | 6.16M | 5.4M |
| Selling, General, and Administrative Revenue Growth | +4.11% | +0.60% | -1.60% | -11.07% | +5.15% | -3.71% | -0.38% | -10.66% | -3.97% | +3.63% | +0.01% | -7.21% | -3.69% | +12.17% | -1.54% | -3.90% | -2.97% | +10.97% | +9.57% | +0.40% | +0.54% | +8.06% | +12.36% | +2.45% | -9.01% | +44.39% | +44.77% | +36.64% | +24.51% | +23.86% | +5.76% | -12.31% | +5.92% | -4.23% | +10.92% | -0.99% | +7.24% | +5.51% | +10.54% | -22.66% | +14.04% | n/a |
| Research and Development Revenue | 32.79M | 34.62M | 33.3M | 36.13M | 38.28M | 35.34M | 39.3M | 35.55M | 31.48M | 32.34M | 30.93M | 31.36M | 44.31M | 42.06M | 44M | 45.81M | 33.98M | 37.05M | 37.19M | 37.04M | 42.59M | 34M | 31.58M | 26.27M | 26.52M | 37.97M | 38.89M | 36.43M | 44.73M | 41.32M | 34.83M | 25.24M | 23.12M | 24.08M | 20.67M | 19.89M | 24.58M | 21.8M | 24.06M | 25.92M | 27.01M | 20.75M |
| Research and Development Revenue Growth | -5.29% | +3.95% | -7.84% | -5.61% | +8.32% | -10.09% | +10.55% | +12.95% | -2.67% | +4.55% | -1.36% | -29.23% | +5.34% | -4.41% | -3.94% | +34.80% | -8.28% | -0.36% | +0.40% | -13.05% | +25.29% | +7.66% | +20.21% | -0.93% | -30.17% | -2.36% | +6.76% | -18.57% | +8.26% | +18.63% | +38.02% | +9.16% | -4.00% | +16.51% | +3.91% | -19.07% | +12.77% | -9.43% | -7.17% | -4.01% | +30.14% | n/a |